Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hematopoietic stem cells (HSCs) are clonogenic progenitor cells capable of self-renewal and multilineage differentiation that reconstitute blood cell populations following transplantation. In HSCT, engraftment describes the process by which donor-derived HSCs home to the recipient's bone marrow niches, proliferate, and restore hematopoiesis. Success depends on the number and quality of transplanted HSCs, supportive marrow microenvironment, and immunological factors[1][3][6]. Engraftment can be accompanied by complications such as graft failure and engraftment syndrome, both reflecting immune dysregulation or insufficient HSC activity[2].
Cell replacement: transplanted HSCs reconstitute hematopoiesis Niche engraftment: HSCs home to bone marrow and proliferate Immunomodulation: immune reconstitution post-transplant
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hematopoietic stem cell (HSC) (HSC).